Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
← catalyst calendarNCT07024706 · readout in 986 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With AbbVie, Genentech, Inc..
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
80estimated
Sites
36
Countries
Austria, Brazil, Czechia +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-04 | actual | When the study began enrolling |
| Primary completion | 2029-05-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2033-03-23 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma (SLL)
Interventions
- Drug: Acalabrutinib — also filed as CALQUENCE®
- Drug: Venetoclax — also filed as Venclexta®, Venclyxto®
Primary outcome
what the primary-completion date above is the date OFOverall Response Rate (ORR)
measured ORR assessed at multiple timepoints during treatment period (each cycle is 28 days). Timepoint for primary analysis is at completion of cycle 14
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed